Skip to Content
MilliporeSigma

H146

4-Hydroxymephenytoin

≥98% (HPLC)

Synonym(s):

(±)-5-Ethyl-5-(4-hydroxyphenyl)-3-methylhydantoin, (±)-5-Ethyl-5-(4-hydroxyphenyl)-3-methylimididazolidine-2,4-dione

Sign In to View Organizational & Contract Pricing.

Select a Size

5 MG

$355.00

$355.00


Check Cart for Availability

Ships Every 4 weeks

About This Item

Empirical Formula (Hill Notation):
C12H14N2O3
CAS Number:
Molecular Weight:
234.25
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
MDL number:

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

4-Hydroxymephenytoin, ≥98% (HPLC)

InChI

1S/C12H14N2O3/c1-3-12(8-4-6-9(15)7-5-8)10(16)14(2)11(17)13-12/h4-7,15H,3H2,1-2H3,(H,13,17)

SMILES string

CCC1(NC(=O)N(C)C1=O)c2ccc(O)cc2

InChI key

OQPLORUDZLXXPD-UHFFFAOYSA-N

assay

≥98% (HPLC)

solubility

DMSO: >5 mg/mL

Quality Level

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
UC126UC175SML1381
assay

≥98% (HPLC)

assay

-

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

200

Quality Level

200

Quality Level

100

solubility

DMSO: >5 mg/mL

solubility

-

solubility

DMSO: soluble

solubility

H2O: 10 mg/mL, clear, DMSO: 5 mg/mL, clear (warmed)

Application

Pharmacological activity investigating:
  • The drug effects on metabolization[1]
  • In vitro cytochrome P450 activity in microsomes[2]

Analyte for electron-capture gas chromatography procedures[3]

General description

CYP2C19 metabolite of mephenytoin.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sonja Krösser et al.
European journal of clinical pharmacology, 62(4), 277-284 (2006-03-10)
The 5HT(1A) receptor agonist sarizotan is in clinical development for the treatment of dyskinesia, a potentially disabling complication in Parkinson's disease. We investigated the effect of sarizotan on the clinical pharmacokinetics of probe drugs for cytochrome P450 (CYP) to evaluate
M. Salsali, et al.,
Journal of Pharmacological and Toxicological Methods, 44, 461-465 (2001)
A Adedoyin et al.
Clinical pharmacology and therapeutics, 64(1), 8-17 (1998-08-08)
Drug metabolism is influenced by liver disease because of the central role that the liver plays in metabolic activities in the body. However, it is still unclear how activities of specific drug-metabolizing enzymes are influenced by the presence and severity
M Tanaka et al.
Clinical pharmacology and therapeutics, 62(6), 619-628 (1998-01-20)
To assess the possible relationship between the metabolic disposition of pantoprazole and genetically determined S-mephenytoin 4'-hydroxylation phenotype and genotype. The pharmacokinetic disposition of pantoprazole was investigated in 14 Japanese male volunteers (seven extensive and seven poor metabolizers of S-mephenytoin). All
C Desiderio et al.
Electrophoresis, 15(1), 87-93 (1994-01-01)
Using cyclodextrin micellar electrokinetic capillary chromatography (CD-MECC), baseline separation of mephenytoin, 4-hydroxymephenytoin and 4-hydroxyphenytoin enantiomers in urine was effected with beta-cyclodextrin. After single-dose administration of 100 mg of racemic mephenytoin, the 0-8 h urine was collected, and enzymatically hydrolyzed urine

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service